Research
Hormonal
Increased abundance of gram-negative bacteria (Dialister and Allisonella) in obese-T2DM patients is associated with elevated lipopolysaccharide (LPS) levels, which mediates inflammatory response and contributes to insulin resistance.
This finding links specific gut bacteria to inflammation and insulin resistance via LPS. It suggests that maintaining gut barrier integrity and avoiding unnecessary antibiotics may be important for metabolic health, although no specific intervention is tested here.
ModerateSupportsMEDIUM confidence
Additionally, we observed that the abundance of gram-negative bacteria (Dialister and Allisonella) increased drastically in the obese-T2DM samples from the Pakistani population. These bacteria are extremely important for their contribution toward the development of disease as their increased abundance might have elevated the lipopolysaccharide (LPS) level in obese-T2DM individuals. The circulating LPS binds with CD14 and mediates an inflammatory response, thus contributing positively to the development of obesity and insulin resistance
Why this rating
Observational data with suggested mechanistic pathway based on cited literature.
Source
Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals
Aftab Ahmad et al. · PLoS ONE · 2019
DOI 10.1371/journal.pone.0226372
cross_sectional · n=60Cited 192×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obese individuals with type 2 diabetes exhibit a distinct gut microbiota signature characterized by increased relative abundance of Firmicutes and decreased abundance of Verrucomicrobia, Bacteroidetes, and Proteobacteria compared to healthy controls.Moderate
- The depletion of Verrucomicrobia in obese-T2DM patients is associated with a loss of anti-inflammatory state and improved insulin sensitivity, potentially allowing the growth of pro-inflammatory Proteobacteria.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →